2020

Treatment of septic shock patients with Adrecizumab resulted in significant and sustained mortality reduction most pronounced in early treated patients Adrecizumab, a product candidate for personalized treatment of septic shock, addresses loss of vascular integrity,

Series E round led by existing top-tier life science investors Wellington Partners and HBM Healthcare Investments Data from AdrenOSS-2 on early treatment start with Adrecizumab in septic shock to be presented at DIVI, December 2-4,

Primary endpoint of AdrenOSS-2 achieved: Adrecizumab was well tolerated and showed a favorable safety profile In this biomarker-guided trial, Adrecizumab demonstrated significant and fast improvement of organ function and a substantial reduction on short-term mortality

Hennigsdorf/Berlin (Germany), September 14, 2020 – Adrenomed AG, the vascular integrity company, announced today that data from the AdrenOSS-2 Phase II clinical trial with Adrecizumab in septic shock (NCT03085758[i]) will be presented during the International

Adrecizumab (HAM8101) showed a favourable outcome in a case series of eight COVID‐19 patients with life-threatening organ failure in ICU At publication, this represented the first data evaluating an experimental therapy in such late-stage COVID-19